HeartLung Corporation's AI-CVD receives FDA clearance for opportunistic multi-condition screening on routine chest CT scans.
Key Details
- 1FDA grants 510(k) clearance to HeartLung Corporation's AI-CVD algorithm.
- 2AI-CVD performs 11 opportunistic screening assessments on chest CT scans.
- 3Assesses for findings like coronary calcium, valve and wall calcium, volumetry, lung and liver attenuation, bone mineral density, and more.
- 4Alerts doctors to incidental findings that may indicate risk for conditions such as heart disease, stroke, osteoporosis, diabetes, and liver steatosis.
- 5Can be used for both new and prior CT scans, supporting broader preventive care.
- 6Platform potentially applicable to nearly 40 million CT scans per year in the U.S.
Why It Matters
This clearance introduces the most comprehensive FDA-cleared AI platform for opportunistic screening on CT, enabling earlier identification of at-risk patients and broadening the utility of routine imaging for preventive care. Radiology practices may see an expanded role in population health management through automated, multi-disease detection.
Source
Cardiovascular Business
Related News
•Radiology Business
SimonMed Imaging Introduces Paid AI Add-Ons for Routine Exams
SimonMed Imaging is launching new AI-powered elective services for routine imaging exams with additional out-of-pocket costs for patients.
•Radiology Business
Aidoc Raises $150M to Expand Imaging AI Portfolio and Global Reach
Aidoc secures $150M in Series E funding led by Goldman Sachs to accelerate expansion of its clinical AI platform.
•Radiology Business
AI Model Outperforms Radiologists in Early Pancreatic Cancer Detection
REMOD, a new AI model, detects pancreatic cancer on CT scans much earlier and more accurately than radiologists.